Showing results (1-10 of 138) with videos related to
Sort By:
Pageof 14
Current Cancer Drug Targets|February 20, 2007
Indoleamine 2,3-dioxygenase in immune suppression and cancerAlexander J Muller, George C PrendergastCancer Research|September 17, 2005
Marrying immunotherapy with chemotherapy: why say IDO?Alexander J Muller, George C PrendergastCancer Journal (Sudbury, Mass.)|January 24, 2023
A Brief Overview of Cancer VaccinesAlexander J Muller, Sunil Thomas, George C PrendergastThe American Journal of Pathology|March 16, 2010
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathwayGeorge C Prendergast, Richard Metz, Alexander J MullerExpert Opinion on Therapeutic Targets|August 9, 2005
Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitorsAlexander J Muller, William P Malachowski, George C PrendergastImmunological Reviews|March 28, 2008
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escapeJessica B Katz, Alexander J Muller, George C PrendergastFrontiers in Oncology|May 14, 2023
IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammationAlexander J Muller, Arpita Mondal, Souvik Dey, et al.Seminars in Immunopathology|September 12, 2018
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyondAlexander J Muller, Mark G Manfredi, Yousef Zakharia, et al.Biochimica Et Biophysica Acta|October 22, 2008
BAR the door: cancer suppression by amphiphysin-like genesGeorge C Prendergast, Alexander J Muller, Arivudanambi Ramalingam, et al.Cancer Research|December 17, 2017
Discovery of IDO1 Inhibitors: From Bench to BedsideGeorge C Prendergast, William P Malachowski, James B DuHadaway, et al.Pageof 14